SEARCH

SEARCH BY CITATION

References

  • 1
    Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology 2010; 113: 713725.
  • 2
    Naleschinski D, Baron R. Complex regional pain syndrome type I: neuropathic or not? Curr Pain Headache Rep 2010; 14: 196202.
  • 3
    Rowbotham MC. Pharmacologic management of complex regional pain syndrome. Clin J Pain 2006; 22: 425429.
  • 4
    Cossins L, Okell RW, Cameron H, Simpson B, Poole HM, Goebel A. Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to February 2012. Eur J Pain 2013; 17: 158173.
  • 5
    Goebel A, Barker C, Turner-Stokes L, Atkins RM, Cameron H, Cossins L, Eedy DJ, Haynes L, Johnson M, Lewis J, McCabe CS, Nurmikko TJ, Okell R, Poole H, Serpell M, Shenker N, Simpson B, Smith BH. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care. London: Royal College of Physicians, 2012.
  • 6
    de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain 2007; 129: 1220.
  • 7
    Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2013. doi: 10.1111/bcp.12094.
  • 8
    Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010; 113: 678684.
  • 9
    Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 1996; 77: 441444.
  • 10
    Kalsi S, Wood D, Dargan P. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal 2011; 4: 110.
  • 11
    Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565575.
  • 12
    Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci 1995; 18: 5456.
  • 13
    Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in ‘wind-up’ of class 2 neurones in the dorsal horn of the rat. Brain Res 1987; 424: 402406.
  • 14
    Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007; 21: 259271.
  • 15
    Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 13011308.
  • 16
    Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6: 5360.
  • 17
    Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study G. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 13331341.
  • 18
    Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856864.
  • 19
    Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338: 6872.
  • 20
    Dolgin E. Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med 2013; 19: 8.
  • 21
    Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; (1): CD004603.
  • 22
    Hirota K, Lambert DG. Ketamine: new uses for an old drug? Br J Anaesth 2011; 107: 123126.
  • 23
    Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002; 96: 725741.
  • 24
    McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004; 98: 13851400. table of contents.
  • 25
    Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573581.
  • 26
    Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147: 107115.
  • 27
    Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145: 304311.
  • 28
    Bell RF, Moore RA. Intravenous ketamine for CRPS: making too much of too little? Pain 2010; 150: 1011.
  • 29
    Harden RN, Swan M, King A, Costa B, Barthel J. Treatment of complex regional pain syndrome: functional restoration. Clin J Pain 2006; 22: 420424.
  • 30
    Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. Pain 2011; 152: 22042205.
  • 31
    Perez RS, Zollinger PE, Dijkstra PU, Thomassen-Hilgersom IL, Zuurmond WW, Rosenbrand KC, Geertzen JH. force CIt. Evidence based guidelines for complex regional pain syndrome type 1. BMC Neurol 2010; 10: 20.
  • 32
    Sear JW. Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data? Pain 2011; 152: 19461947.
  • 33
    Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A, Sarton EY. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain 2011; 152: 21732178.
  • 34
    Bell RF. Ketamine for chronic noncancer pain: concerns regarding toxicity. Current opinion in supportive and palliative care 2012; 6: 183187.
  • 35
    Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010; 11: 24172429.
  • 36
    Koffler SP, Hampstead BM, Irani F, Tinker J, Kiefer RT, Rohr P, Schwartzman RJ. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol 2007; 22: 719729.
  • 37
    Kiefer RT, Rohr P, Ploppa A, Dieterich HJ, Grothusen J, Koffler S, Altemeyer KH, Unertl K, Schwartzman RJ. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med 2008; 9: 11731201.
  • 38
    Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig 2009; 29: 317324.
  • 39
    Gustin SM, Schwarz A, Birbaumer N, Sines N, Schmidt AC, Veit R, Larbig W, Flor H, Lotze M. NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. Pain 2010; 151: 6976.
  • 40
    Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, Schaller HE, Haerle M. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007; 23: 237243.
  • 41
    Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, Sarton EY. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011; 152: 656663.
  • 42
    Stanton-Hicks MD, Burton AW, Bruehl SP, Carr DB, Harden RN, Hassenbusch SJ, Lubenow TR, Oakley JC, Racz GB, Raj PP, Rauck RL, Rezai AR. An updated interdisciplinary clinical pathway for CRPS: report of an expert panel. Pain Pract 2002; 2: 116.
  • 43
    Flor H. Cortical reorganisation and chronic pain: implications for rehabilitation. J Rehabil Med 2003; 41(Suppl): 6672.
  • 44
    Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Cortical reorganization during recovery from complex regional pain syndrome. Neurology 2004; 63: 693701.
  • 45
    Bailey J, Nelson S, Lewis J, McCabe CS. Imaging and clinical evidence of sensorimotor problems in CRPS: utilizing novel treatment approaches. J Neuroimmune Pharmacol 2013; 8: 564575.
  • 46
    Chizh BA, Headley PM. NMDA antagonists and neuropathic pain–multiple drug targets and multiple uses. Curr Pharm Des 2005; 11: 29772994.
  • 47
    Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Immpact. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 919.